Skip to main content

Table 1 Baseline patient characteristics in two groups

From: Predictors of contrast-induced acute kidney injury in patients with coronary artery disease receiving contrast agents twice within 30 days

ItemGroup A (n = 559)Group B (n = 48)P value
Age (year, x ± s)60.2 ± 11.061.5 ± 12.70.438
Female [n(%)]121 (21.6)14 (29.1)0.229
Weight (kg, x ± s)71.7 ± 11.772.1 ± 11.70.821
Height (cm, x ± s)169.9 ± 6.6170.3 ± 6.70.699
BMI (kg/m2, x ± s)24.8 ± 3.624.9 ± 3.70.930
Current smoker [n(%)]288 (51.5)27 (56.2)0.529
Current alcohol [n(%)]180 (32.2)14 (29.1)0.665
STEMI [n(%)]196 (35.0)22 (45.8)0.136
Hypertension [n(%)]303 (54.2)33 (68.7)0.061
Diabetes [n(%)]132 (23.6)16 (33.3)0.132
CKD [n(%)]34 (6.1)6 (12.5)0.119
Stroke [n(%)]53 (9.5)8 (16.7)0.130
Cancer [n(%)]4 (0.7)01.000
Peripheral vascular disease [n(%)]7 (1.3)2 (4.2)0.109
Ulcer [n(%)]58 (10.4)4 (8.3)0.807
NYHA class II-III [n(%)]109 (19.5)15 (31.3)0.053
SBP (mmHg, x ± s)133.9 ± 21.9136.8 ± 22.40.379
DBP (mmHg, x ± s)79.3 ± 13.480.85 ± 13.50.426
HR (beat/min, x ± s)76.4 ± 14.181.4 ± 17.30.022
Basic-Scr (μmol/L, x ± s)77.4 ± 25.075.1 ± 24.50.548
Basic-eGFR [ml/(min•1.73m2), x ± s]108.4 ± 41.5110.0 ± 43.00.908
BUN (mmol/L, x ± s)5.9 ± 1.96.1 ± 1.30.638
K+ (mmol/L, x ± s)4.1 ± 0.44.2 ± 0.30.243
Na+ (mmol/L, x ± s)140.1 ± 3.4139.6 ± 3.00.391
PLT (× 109/L, x ± s)208.8 ± 55.8209.5 ± 55.40.943
WBC (×109/L, x ± s)8.3 ± 3.18.3 ± 2.80.995
Hb (g/L, x ± s)137.9 ± 24.1136.2 ± 17.40.671
TC (mmol/L, x ± s)4.2 ± 1.34.1 ± 1.00.819
TG [mmol/L, M(Q1, Q3)]a1.48 (1.13,1.72)1.44 (0.72,1.98)0.367
ALT [mmol/L, M(Q1, Q3)]a26.00 (13,81)24.00 (9,63)0.975
AST [mmol/L, M(Q1, Q3)]a25.00 (7,76)23.00 (4,67)0.250
ALB (mmol/L, x ± s)33.2 ± 20.535.3 ± 15.50.718
HDL-C (mmol/L, x ± s)1.2 ± 0.41.0 ± 0.30.684
LDL-C (mmol/L, x ± s)2.4 ± 1.02.4 ± 0.90.790
Glucose (mmol/L, x ± s)6.6 ± 2.97.2 ± 3.40.337
CK [U/L, M(Q1, Q3)]a137.00 (27.31,452.50)108.00 (45.79,168.75)0.303
CK-MB [U/L, M(Q1, Q3)]a17.00 (7.14,22.75)17.00 (6.34,16.75)0.936
TNT [ng/L, M(Q1, Q3)]a0.05 (0.01,0.523)0.05 (0.01,0.162)0.241
NT-proBNP [μg/L, M(Q1, Q3)]a83.00 (12.00,1085.00)140.00 (21.00,2050.00)0.236
LV (mm, x ± s)48.8 ± 6.449.8 ± 5.80.687
EF (%, x ± s)58.9 ± 10.757.6 ± 11.60.730
Medicine care [n(%)]
 Diuretics210 (37.6)27 (56.3)0.011
 CCB231 (41.3)21 (43.8)0.743
 β-RB469 (83.9)40 (83.3)0.918
 ACEI/ARB444 (79.4)34 (70.8)0.162
 Statins366 (65.5)37 (77.1)0.102
 Digitalis103 (18.4)17 (35.4)0.005
  1. Group A No CI-AKI from second agent, Group B CI-AKI from second agent, BMI Body mass index, STEMI ST-segment elevation myocardial infarction, CKD Chronic kidney disease, NYHA New York Heart Association, SBP Systolic blood pressure, DBP Diastolic blood pressure, HR Heart rate, Scr Serum creatinine, eGFR Estimated glomerular filtration rate, BUN Blood urea nitrogen, PLT Platelets, WBC White blood cells, Hb Hemoglobin, TC Total cholesterol, TG Triglycerides, ALT Alanine aminotransferase, AST Aspartate aminotransferase, ALB Albumin, HDL-C High-density lipoprotein cholesterol, LDL-C Low-density lipoprotein cholesterol, CK Creatine kinase, CK-MB Creatine kinase-myocardial band, TNT Troponin T, NT-proBNP N-terminal pro-brain natriuretic peptide, LV Left ventricular, EF Ejection fraction, CCB Calcium channel blocker, β-RB β-receptor blocker, ACEI Angiotensin-converting enzyme inhibitor, ARB Angiotensin II receptor antagonist
  2. aMeans nonnormally distributed continuous variables